Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etrumadenant + zimberelimab + m-FOLFOX-6 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
A combination regimen composed of four agents: **etrumadenant** (an adenosine A2a/A2b receptor antagonist immunotherapy), **zimberelimab** (a PD-1 monoclonal antibody checkpoint inhibitor), **m-FOLFOX-6** (a standard chemotherapeutic combination of oxaliplatin, leucovorin, and 5-fluorouracil given in a modified dosing schedule), and **bevacizumab** (a monoclonal antibody inhibitor of vascular endothelial growth factor, antiangiogenic). This multi-agent protocol is under investigation primarily for various solid tumors, particularly gastrointestinal cancers such as colorectal cancer. The regimen is designed to combine immunotherapy, antiangiogenic, and cytotoxic chemotherapy to leverage distinct, potentially synergistic mechanisms of tumor killing and immune modulation.
- Other names
- modified FOLFOX6FOLFOX6FOLFOX-6FOLFOX 65-fluorouracil + leucovorin + oxaliplatin
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA3 (Adenosine A3 receptor)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on etrumadenant + zimberelimab + m-FOLFOX-6 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etrumadenant + zimberelimab + m-FOLFOX-6 + bevacizumab.